Efficacy and safety of weekly intravenous nanoparticle albumin‐bound paclitaxel for non‐small cell lung cancer patients who have failed at least two prior systemic treatments

The study was conducted to evaluate the efficacy and safety of weekly intravenous nanoparticle albumin‐bound paclitaxel (NAB‐paclitaxel) treatment in patients with advanced non‐small‐cell lung cancer (NSCLC) who have undergone multi‐line therapy, and to investigate the association of secreted protein acidic and rich in cysteine (SPARC) expression status with clinical outcome.

• Publication year

  2017

• Venue

  Thoracic Cancer

• Publication date

  2017-03-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/1759-7714.12413PMID 28304139PMCID 5415477
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2015

  2015cited by this paper
• Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer.

  2014cited by this paper
• Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer.

  2013cited by this paper
• 苹果酸舒尼替尼治疗多次复发的晚期非小细胞肺癌疗效与安全性分析

  2013cited by this paper
• Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

  2012cited by this paper
• Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

  2012cited by this paper
• A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

  2010cited by this paper
• 1004 SPARC may be a predictive biomarker of response to nab-paclitaxel

  2009cited by this paper
• Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

  2008cited by this paper
• Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.

  2008cited by this paper
• Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.

  2007cited by this paper
• Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.

  2007cited by this paper
• Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.

  2006cited by this paper
• Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.

  2006cited by this paper
• The natural history of the incidentally discovered small simple pancreatic cyst: long-term follow-up and clinical implications.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.

  2005cited by this paper
• Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes.

  2005cited by this paper
• Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.

  2005cited by this paper
• Overexpression of SPARC gene in human gastric carcinoma and its clinic–pathologic significance

  2004cited by this paper
• Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  2004cited by this paper
• Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients.

  2003cited by this paper
• SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system.

  2003cited by this paper
• Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression

  2003cited by this paper
• Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer.

  2003cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

  2002cited by this paper
• Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells

  2002cited by this paper
• Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

  2000cited by this paper
• Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

  2000cited by this paper
• Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

  2000cited by this paper
• Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer.

  1999cited by this paper
• Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone.

  1999cited by this paper
• Cancer statistics

  1989cited by this paper

• Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer

  2025cites this paper
• Lysosomal nanotoxicity: Impact of nanomedicines on lysosomal function.

  2023cites this paper
• Prognostic significance of SPARC expression in non-small cell lung cancer: A meta-analysis and bioinformatics analysis

  2022cites this paper
• Gastric cancer biomarker analysis in patients treated with different adjuvant chemotherapy regimens within SAMIT, a phase III randomized controlled trial

  2022cites this paper
• Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy.

  2021cites this paper
• Investigating the relationship between secreted protein acidic and rich in cysteine expression level and therapeutic efficacy of nab-paclitaxel: a meta-analysis

  2021cites this paper
• Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen

  2020cites this paper
• Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma

  2020cites this paper
• Recent advances in targeted nanomedicine as promising antitumor therapeutics.

  2020cites this paper
• A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer

  2019cites this paper
• Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency

  2019cites this paper
• SPARC acts as a mediator of TGF‐&bgr;1 in promoting epithelial‐to‐mesenchymal transition in A549 and H1299 lung cancer cells

  2018cites this paper
• Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence

  2018cites this paper
• The revolution of lung cancer treatment: from vaccines, to immune checkpoint inhibitors, to chimeric antigen receptor T therapy

  2017cites this paper